Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research

Executive Summary: Olaparib (AZD2281, Ku-0059436) is a potent and highly selective inhibitor of poly(ADP-ribose) polymerase-1 and -2 (PARP-1/2), vital in DNA repair processes [APExBIO]. It exhibits nanomolar IC50 values (PARP1: 5 nM, PARP2: 1 nM) and preferentially targets BRCA-deficient tumor cells by exploiting homologous recombination deficiency [Jiang et al., 2024]. Olaparib enhances radiosensitivity in xenograft models and is widely used in DNA damage response and tumor radiosensitization studies [Jiang et al., 2024]. Its efficacy is modulated by ATM kinase activity, with ATM-deficient cells showing increased susceptibility. APExBIO supplies validated Olaparib (A4154) for reproducible research workflows.

Biological Rationale

PARP-1 and PARP-2 enzymes are central to the repair of single-strand DNA breaks via the base excision repair pathway. Inhibition of PARP activity leads to the accumulation of DNA lesions, which become cytotoxic if not properly resolved. Tumors with defective homologous recombination repair—most notably those with BRCA1 or BRCA2 mutations—are unable to compensate for PARP inhibition, resulting in synthetic lethality and tumor cell death (Jiang et al., 2024). This biological vulnerability underpins the clinical and preclinical utility of selective PARP inhibitors like Olaparib in BRCA-associated cancers.

Mechanism of Action of Olaparib (AZD2281, Ku-0059436)

Olaparib is a small-molecule inhibitor with high affinity for both PARP-1 and PARP-2, with IC50 values of 5 nM and 1 nM, respectively, measured in biochemical assays at pH 7.5 and 25°C (APExBIO). By binding to the catalytic domain of these enzymes, Olaparib prevents PARylation and the recruitment of DNA repair complexes. In BRCA-deficient cells, the inability to efficiently repair DNA double-strand breaks following PARP inhibition leads to apoptosis. In addition, Olaparib increases radiosensitivity in non-small cell lung carcinoma (NSCLC) xenograft models by enhancing DNA damage and improving tumor perfusion (Jiang et al., 2024). The compound's selectivity for cancer cells with homologous recombination deficiency limits off-target cytotoxicity in normal tissues.

Evidence & Benchmarks

• Olaparib inhibits PARP-1 with an IC50 of 5 nM and PARP-2 with an IC50 of 1 nM in enzymatic assays (APExBIO, product page).
• BRCA-deficient ovarian cancer cells are selectively killed by Olaparib due to synthetic lethality (Jiang et al., 2024, DOI).
• Olaparib enhances radiosensitivity in NSCLC xenograft models by increasing DNA damage and tumor perfusion (Jiang et al., 2024, DOI).
• ATM kinase deficiency increases sensitivity to Olaparib in cell-based assays (Jiang et al., 2024, DOI).
• Typical experimental conditions: 10 μM Olaparib treatment for 1 hour in cell culture; 50 mg/kg/day intraperitoneal dosing for 14 days in mice (APExBIO, product page).

For a deeper dive into experimental design and troubleshooting, see Olaparib (AZD2281): Elevating BRCA-Deficient Cancer Research, which provides actionable protocols and advanced guidance. This article expands upon those foundations by focusing on benchmarked selectivity data and updated radiosensitization findings.

Applications, Limits & Misconceptions

Olaparib (A4154) is extensively applied in:

• DNA damage response assays in BRCA-deficient and homologous recombination-deficient models.
• Tumor radiosensitization studies, especially in NSCLC and ovarian cancer models.
• Targeted therapy research for BRCA-associated cancers.
• Dissecting caspase signaling pathway involvement in PARP-mediated apoptosis.

For scenario-driven and evidence-based guidance on maximizing reproducibility, see Olaparib (AZD2281, Ku-0059436): Optimizing BRCA-Deficient..., which discusses real-world experimental challenges and vendor selection. This current article extends those discussions by clarifying Olaparib's role in radiosensitization and cross-validating its selectivity benchmarks.

Common Pitfalls or Misconceptions

• Olaparib is not universally cytotoxic: Its efficacy is primarily observed in cells deficient in homologous recombination (e.g., BRCA1/2 mutations); wild-type cells show limited sensitivity (Jiang et al., 2024).
• ATM-proficient cells may exhibit reduced Olaparib sensitivity: ATM kinase activity can modulate the cellular response to PARP inhibition.
• Not directly interchangeable with other PARP inhibitors: Olaparib's pharmacokinetics, selectivity, and off-target profiles differ from agents like niraparib or rucaparib.
• Solubility limits experimental design: Olaparib is insoluble in water and ethanol; DMSO is required for stock solutions, affecting some downstream assays (see storage and solubility guidelines below).
• Not suitable for long-term solution storage: Olaparib solutions are not recommended for storage above -20°C or for extended periods due to degradation risk.

For robust protocols and troubleshooting advice, see Solving Laboratory Challenges with Olaparib (AZD2281, Ku-...), which offers practical insights into reproducibility and workflow reliability; this article provides updated selectivity and mechanistic boundaries based on recent benchmark studies.

Workflow Integration & Parameters

• Preparation: Olaparib is soluble in DMSO at concentrations ≥21.72 mg/mL (~48.1 mM at 434.5 g/mol).
• Storage: Stock solutions should be kept below -20°C; avoid repeated freeze-thaw cycles.
• In vitro: Standard treatment is 10 μM for 1 hour in cell culture; adjust based on cell line sensitivity and endpoint assay.
• In vivo: Typical dosing is 50 mg/kg/day intraperitoneally for 14 days in mouse xenograft models.
• Controls: Always include DMSO-only and PARP-wild-type controls for specificity assessment.
• Vendor validation: APExBIO's Olaparib (A4154) is batch-validated for purity and reproducibility, ensuring experimental confidence in DNA damage response and radiosensitization assays (product page).

Conclusion & Outlook

Olaparib (AZD2281, Ku-0059436) has established itself as a selective and potent PARP-1/2 inhibitor, pivotal for research in BRCA-deficient cancer models and DNA damage response pathways (Jiang et al., 2024). Its mechanism-driven selectivity, nanomolar potency, and validated protocols—especially as supplied by APExBIO—make it a preferred reagent for targeted therapy and radiosensitization studies. Ongoing research is clarifying its limitations, particularly regarding ATM status and off-target effects, and optimizing its use for translational applications. For the latest protocols and experimental troubleshooting, researchers should consult both product documentation and current peer-reviewed literature.